Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence
| Status: | Completed |
|---|---|
| Conditions: | Overactive Bladder, Urology |
| Therapuetic Areas: | Gastroenterology, Nephrology / Urology |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 3/30/2013 |
| Start Date: | October 2010 |
| End Date: | September 2013 |
| Contact: | Allergan Inc. |
| Email: | clinicaltrials@allergan.com |
This study will evaluate the safety and efficacy of AGN-214868 in patients with idiopathic
overactive bladder (IOAB) and urinary incontinence.
Inclusion Criteria:
- If female, must be of nonreproductive potential
- If male, must agree to use acceptable contraception
- Symptoms of overactive bladder with urinary urgency incontinence
- Inadequate response or limiting side effects with anticholinergics for the treatment
of OAB
Exclusion Criteria:
- Overactive bladder caused by neurological condition (eg, spinal cord injury, multiple
sclerosis)
- History of bladder surgery
- Treatment with botulinum toxin therapy of any serotype for any non-urological
condition within the prior 12 weeks
- Previous treatment with botulinum toxin therapy of any serotype for any urological
condition
We found this trial at
1
site
Click here to add this to my saved trials
